My question is this. What is the actual financial benefit for PAR in repurposing this drug. Doesn't the original patent holder still stand to benefit? How does this work for PAR?
Enlighten me please.
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 27.5¢ | 27.5¢ | $672 | 2.444K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 144697 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 10.13am 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |